- Home
- BCAT vs ARDX Comparison
BCAT vs ARDX Comparison
Compare BCAT & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAT
- ARDX
- Stock Information
- Founded
- BCAT 2020
- ARDX 2007
- Country
- BCAT United States
- ARDX United States
- Employees
- BCAT N/A
- ARDX N/A
- Industry
- BCAT Finance/Investors Services
- ARDX Biotechnology: Pharmaceutical Preparations
- Sector
- BCAT Finance
- ARDX Health Care
- Exchange
- BCAT Nasdaq
- ARDX Nasdaq
- Market Cap
- BCAT 1.7B
- ARDX 1.4B
- IPO Year
- BCAT N/A
- ARDX 2014
- Fundamental
- Price
- BCAT $15.36
- ARDX $5.06
- Analyst Decision
- BCAT
- ARDX Buy
- Analyst Count
- BCAT 0
- ARDX 8
- Target Price
- BCAT N/A
- ARDX $9.93
- AVG Volume (30 Days)
- BCAT 308.8K
- ARDX 3.6M
- Earning Date
- BCAT 01-01-0001
- ARDX 02-20-2025
- Dividend Yield
- BCAT 9.38%
- ARDX N/A
- EPS Growth
- BCAT N/A
- ARDX N/A
- EPS
- BCAT 1.43
- ARDX N/A
- Revenue
- BCAT N/A
- ARDX $333,615,000.00
- Revenue This Year
- BCAT N/A
- ARDX $169.30
- Revenue Next Year
- BCAT N/A
- ARDX $14.87
- P/E Ratio
- BCAT $11.41
- ARDX N/A
- Revenue Growth
- BCAT N/A
- ARDX 168.06
- 52 Week Low
- BCAT $13.67
- ARDX $4.32
- 52 Week High
- BCAT $16.38
- ARDX $9.83
- Technical
- Relative Strength Index (RSI)
- BCAT 39.90
- ARDX 41.70
- Support Level
- BCAT $15.62
- ARDX $5.37
- Resistance Level
- BCAT $15.91
- ARDX $6.55
- Average True Range (ATR)
- BCAT 0.14
- ARDX 0.31
- MACD
- BCAT -0.02
- ARDX -0.02
- Stochastic Oscillator
- BCAT 16.67
- ARDX 0.67
About BCAT BlackRock Capital Allocation Term Trust of Beneficial Interest
BlackRock Capital Allocation Trust is a non-diversified, closed-end management investment company. The investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation.
About ARDX Ardelyx Inc.
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.